← Back to Search

Cannabinoid

CBD Oral Disintegrating Tablet (ODT) for Infections

Phase 2 & 3
Waitlist Available
Led By Michael Alaia, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 14 post-surgery

Summary

This trial is testing whether CBD can help manage pain after shoulder surgery. It will compare CBD's effectiveness to that of opioid painkillers. CBD might work by reducing pain and swelling through its interaction with the body's natural pain control system. CBD has been studied for its potential benefits in managing chronic pain and has shown promise as a non-intoxicating alternative to opioids.

Eligible Conditions
  • Infections
  • Postoperative Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 14 post-surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 14 post-surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Nausea Score on VAS Scale
Pain Visual Analog Scale (VAS) Score
Secondary study objectives
Number of Completed Doses Out of 3 Maximum Doses/Day
Patient Satisfaction Score
Total Opioid Consumption

Side effects data

From 2022 Phase 2 & 3 trial • 100 Patients • NCT04672252
8%
Elevated alanine transaminase
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 1 - CBD
Cohort 2 - Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cohort 1 - CBDExperimental Treatment1 Intervention
Group II: Cohort 2 - PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBD Oral Disintegrating Tablet (ODT)
2020
Completed Phase 3
~100

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,407 Previous Clinical Trials
855,670 Total Patients Enrolled
11 Trials studying Infections
55,497 Patients Enrolled for Infections
Orcosa Inc.UNKNOWN
1 Previous Clinical Trials
100 Total Patients Enrolled
Michael Alaia, MDPrincipal InvestigatorNYU Langone Health
3 Previous Clinical Trials
168 Total Patients Enrolled
~20 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top